NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

MULTIPLE TECHNOLOGY APPRAISAL

MTA: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (including reviews of technology appraisal guidance 91 and 222) [ID468]

The following documents are made available to the consultees and commentators:

1. **Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)**

2. **Consultee and commentator comments on the Appraisal Consultation Document** from:
   - PharmaMar
   - Healthcare Improvement Scotland
   - *Royal College of Nursing – no comments*
   - *Department of Health – no comments*
   - *Roche Products – no comments*

3. **Assessment Group responses –** by BMJ-TAG

Any information supplied to NICE which has been marked as confidential, has been redacted. All personal information has also been redacted.